Immunohistochemical Study of Estrogen and Progesterone Receptor in Thai Swamp Buffalo Oviductal Epithelium at Follicular and Luteal Phase

被引：0
|
作者：
Tienthai, P. [1 ]
Sajjarengpong, K. [1 ]
Techakumphu, M. [1 ]
机构：
[1] Chulalongkorn Univ, Fac Vet Sci, Dept Anat, Bangkok 10330, Thailand
来源：
15TH CONGRESS OF THE FEDERATION OF ASIAN VETERINARY ASSOCIATIONS, FAVA-OIE JOINT SYMPOSIUM ON EMERGING DISEASES, PROCEEDINGS | 2008年
关键词：
Buffaloea; Estrogen; Estrous cycle; Oviduct; Progesterone;
D O I：
暂无
中图分类号：
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号：
0905 ;
摘要：
引用
收藏
页码：P257 / P259
页数：3
相关论文
共 49 条
  • [41] Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)
    Friedlander, M.
    Benson, C.
    O'Connell, R. L.
    Reed, N.
    Clamp, A.
    Lord, R.
    Millan, D.
    Nottley, S.
    Amant, F.
    Steer, C.
    Anand, A.
    Mileshkin, L.
    Beale, P.
    Banerjee, S.
    Bradshaw, N.
    Kelly, C.
    Carty, K.
    Divers, L.
    Alexander, L.
    Edmondson, R.
    GYNECOLOGIC ONCOLOGY, 2021, 161 (01) : 160 - 165
  • [42] THE EFFECTS OF AN ANTIPROGESTIN, MIFEPRISTONE, AND AN ANTIESTROGEN, TAMOXIFEN, ON ENDOMETRIAL 17-BETA-HYDROXYSTEROID DEHYDROGENASE AND PROGESTIN AND ESTROGEN-RECEPTORS DURING THE LUTEAL-PHASE OF THE MENSTRUAL-CYCLE - AN IMMUNOHISTOCHEMICAL STUDY
    MAENTAUSTA, O
    SVALANDER, P
    DANIELSSON, KG
    BYGDEMAN, M
    VIHKO, R
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (04): : 913 - 918
  • [43] Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer
    Bonaventura, Anthony
    O'Connell, Rachel L.
    Mapagu, Cristina
    Beale, Philip J.
    McNally, Orla M.
    Mileshkin, Linda R.
    Grant, Peter T.
    Hadley, Alison M.
    Goh, Jeffery C. H.
    Sjoquist, Katrin M.
    Martyn, Julie
    DeFazio, Anna
    Scurry, James
    Friedlander, Michael L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (05) : 900 - 906
  • [44] PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary
    Banerjee, Susana N.
    Tang, Monica
    O'Connell, Rachel
    Clamp, Andrew R.
    Lord, Rosemary
    Mullassery, Vinod Menon
    Hall, Marcia
    Gourley, Charlie
    Bonaventura, Tony
    Goh, Jeffrey C.
    Sykes, Peter
    Grant, Peter T.
    McNally, Orla
    Edmondson, Richard J.
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
    Rayson, Daniel
    Lupichuk, Sasha
    Potvin, Kylea
    Dent, Susan
    Shenkier, Tamara
    Dhesy-Thind, Sukhbinder
    Ellard, Susan L.
    Prady, Catherine
    Salim, Muhammad
    Farmer, Patricia
    Allo, Ghasson
    Tsao, Ming-Sound
    Allan, Alison
    Ludkovski, Olga
    Bonomi, Maria
    Tu, Dongsheng
    Hagerman, Linda
    Goodwin, Rachel
    Eisenhauer, Elizabeth
    Bradbury, Penelope
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (01) : 109 - 116
  • [46] Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
    Daniel Rayson
    Sasha Lupichuk
    Kylea Potvin
    Susan Dent
    Tamara Shenkier
    Sukhbinder Dhesy-Thind
    Susan L. Ellard
    Catherine Prady
    Muhammad Salim
    Patricia Farmer
    Ghasson Allo
    Ming-Sound Tsao
    Alison Allan
    Olga Ludkovski
    Maria Bonomi
    Dongsheng Tu
    Linda Hagerman
    Rachel Goodwin
    Elizabeth Eisenhauer
    Penelope Bradbury
    Breast Cancer Research and Treatment, 2016, 157 : 109 - 116
  • [47] PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
    Kok, Peey-Sei
    Beate, Philip
    O'Connell, Rachel L.
    Grant, Peter
    Bonaventura, Tony
    Scurry, James
    Antill, Yoland
    Goh, Jeffrey
    Sjoquist, Katrin
    DeFazio, Anna
    Mapagu, Cristina
    Amant, Frederic
    Friedlander, Michael
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (05)
  • [48] Phase II trial evaluating addition of fulvestrant to eriotinib in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who are stable on eriotinib and exhibit immunohistochemical (IHC) or PCR positivity for estrogen or progesterone receptor (PR)
    Bazhenova, L.
    Quintana, R.
    Hastings, R. H.
    Messer, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
    Hamilton, Erika
    Pusztai, Lajos
    Soliman, Hatem H.
    Hurvitz, Sara
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    Marreddy, Priya
    Sahmoud, Tarek
    Ibrahim, Nuhad
    CANCER RESEARCH, 2023, 83 (05)
12345